Archives
-
Dacomitinib: From ErbB Blockade to Ferroptosis Assays
2026-08-25
Explore how Dacomitinib and PF-00299804 can be used to dissect ErbB signaling, apoptosis, and mitochondrial ferroptosis susceptibility. This article translates METTL17 findings into a practical assay strategy while clearly separating established evidence from exploratory hypotheses.
-
Resazurin Sodium Salt in iPSC-CF Testing
2026-08-25
Patient-derived iPSC airway models are making cystic fibrosis drug testing more genotype-aware, but translational decisions require both disease-specific functional measurements and robust cell-state controls. This article positions Resazurin sodium salt as a complementary redox-based readout for viability, metabolic activity, assay quality, and screening scalability—not as a substitute for direct CFTR function assays.
-
11β-HSD1 Inhibition, Notch, and NK Cells in Fibrosis
2026-08-24
A 2025 mouse study identifies a dual immunometabolic mechanism by which 11β-HSD1 inhibition reduces thioacetamide-induced liver fibrosis. The work links lower intrahepatic cortisol to suppression of Notch signaling and enhanced natural killer cell-mediated clearance of activated hepatic stellate cells, offering a mechanistic framework for liver fibrosis research.
-
Hypoxia, S100A10, and GBM Chemoresistance
2026-08-24
The reference study identifies hypoxia-induced S100A10 as a driver of glioblastoma proliferation, glycolytic activity, apoptosis suppression, and temozolomide resistance through PI3K–AKT signaling. Its integrative use of public datasets, molecular assays, metabolic measurements, and cell-death analysis provides a framework for connecting tumor microenvironmental stress with treatment failure.
-
DNA Frameworks Improve Enzymatic Oligonucleotide Synthesis
2026-08-23
The reference study introduces tetrahedral DNA nanostructures as an ordered interface that improves primer presentation, enzyme accessibility, and reaction performance in enzymatic oligonucleotide synthesis. Its TDN-based system reduced deletion errors in patterned sequences and achieved a reported 96.82% stepwise yield while encoding 15 bytes of text in a 60-nucleotide DNA fragment.
-
TPPU: Soluble Epoxide Hydrolase Inhibitor Workflows
2026-08-22
TPPU is a nanomolar soluble epoxide hydrolase inhibitor for connecting fatty acid epoxide signaling with inflammation, pain, redox biology, and osteoclastogenesis. This workflow-oriented guide shows how to prepare, apply, and troubleshoot TPPU in cellular, biochemical, and preclinical research without overstating translational maturity.
-
SW033291: 15-PGDH Inhibitor Workflows
2026-08-21
SW033291 provides a practical way to elevate prostaglandin E2 while testing 15-PGDH-dependent regeneration, hematopoiesis, and muscle repair pathways. This guide connects enzyme and cell assays with translational study designs, including the emerging combination of 15-PGDH inhibition and semaglutide during muscle recovery.
-
EZ Cap™ mCherry mRNA: Cap 1 Reporter
2026-08-20
EZ Cap™ mCherry mRNA is a capped red fluorescent protein mRNA designed for transient reporter expression with reduced innate immune stimulation. Its Cap 1 structure, 5mCTP and ψUTP substitutions, and approximately 100-nucleotide poly(A) tail support practical mRNA stability and translation enhancement.
-
Moesin as a Biomarker of Endothelial Injury in Sepsis
2026-08-20
This study integrates patient observations, sepsis models in mice, and human microvascular endothelial-cell experiments to position moesin as a candidate marker of endothelial injury and disease severity. Its findings also connect circulating moesin with ROCK1/MLC and NF-κB signaling, providing a mechanistic basis for further biomarker and barrier-function research.
-
Annexin V-FITC/PI Apoptosis Assay Kit
2026-08-19
The Annexin V-FITC/PI Apoptosis Assay Kit supports rapid separation of viable, early apoptotic, and membrane-compromised cell populations using phosphatidylserine externalization and PI uptake. It is intended for research-use apoptosis assay workflows, not diagnostic testing or standalone identification of a specific cell-death mechanism.
-
Cytarabine (AraC) Workflows for Cell Death Research
2026-08-19
Build reproducible Cytarabine workflows that connect DNA synthesis blockade with dCK-dependent response, p53 signaling, and apoptotic readouts. The approach also shows how AraC experiments can be extended cautiously into virus-associated cell-death studies without confusing apoptosis with necroptosis.
-
LBP Activates Mitophagy to Protect Muscle in Obesity
2026-08-18
A 2025 study shows that Lycium barbarum polysaccharide (LBP) alleviates high-fat-diet-associated skeletal muscle atrophy by engaging the AMPK/PINK1/Parkin mitophagy pathway. Its combined mouse and cell-model evidence links improved glucose–lipid handling with mitochondrial quality control, while pharmacological and genetic perturbations support pathway dependence.
-
FH1 Small Molecule for iHep Maturation
2026-08-18
FH1 (Catalog No. B3700) supports more functional iPS-derived hepatocyte-like cultures by improving albumin secretion, CYP3A4 expression, colony morphology, and AFP profiles. This practical guide covers pilot dosing, maturation readouts, assay integration, and troubleshooting for liver cell research.
-
Cell Counting Kit-8 Plus: Mechanism and Workflow
2026-08-17
Cell Counting Kit-8 Plus is a WST-8-based tetrazolium salt assay for rapid, quantitative measurement of viable-cell-associated metabolic activity. Its sensitivity and short 0.5–1 hour assay window support cell proliferation assay, cytotoxicity assay, and drug screening workflows when results are interpreted within a validated linear range.
-
Dabigatran etexilate in Cell Assays
2026-08-17
Learn how Dabigatran etexilate (SKU A8381) can support mechanistic cell viability, proliferation, and cytotoxicity workflows involving thrombin-rich or plasma-containing systems. This scenario-based guide covers solvent compatibility, concentration design, data interpretation, and practical product-selection criteria.